Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops and commercializes AI-driven DNA biomarker tests for cardiovascular disease. Its core products, Epi+Gen CHD and PrecisionCHD, are designed to help assess coronary heart disease risk and support diagnosis and management of disease. The company was formed around technology invented at the University of Iowa and is building a business around clinical adoption through providers, channel partners, and employers. It operates as an early-stage diagnostic company with a single operating segment focused on product testing and a business model that depends on expanding test utilization and reimbursement acceptance.

−43 297,4 %

−43 832,5 %

−57,5 %

9.79

9.79

— Cardio Diagnostics Holdings, Inc.
%
Cardiovascular diagnostic tests100% Commercial blood- and DNA-based tests used to assess coronary heart disease risk and support diagnosis/management.
Testing platform and clinical workflow0% The underlying AI-driven biomarker technology and lab-enabled workflow used to deliver the tests.

Cardio sells primarily to provider organizations that order tests for patients and use the results in clinical...

  • Provider organizationsprimary

    Clinics and medical groups order Epi+Gen CHD and PrecisionCHD to assess cardiovascular risk and support diagnosis/management.

  • Employerssecondary

    Employers buy testing for prevention and health-screening programs, often through minimum-volume arrangements.

  • Channel partnerssecondary

    Partners help distribute the tests and expand access into new verticals and local markets.

  • Patientsemerging

    Patients may pay directly when the test is not fully covered or when it is offered through a provider program.

Cardio is headquartered in the United States and its business is still primarily domestic...

  • •United States is the core market and headquarters location
  • •India is the first disclosed international expansion market
  • •Domestic growth depends on onboarding provider organizations
  • •Community and wellness partnerships support U.S. market access
  • •No manufacturing footprint was disclosed; operations are service/lab based

Cardio’s strategy is to drive adoption of its clinical solutions among providers, channel partners, and employers...

01
Provider adoption and test utilization rampshort-term

Revenue depends on onboarding organizations and then increasing test volume over the following quarters.

02
Partnership-led commercializationmedium-term

Channel partners and employers can broaden access without relying only on direct sales.

03
Geographic expansionmedium-term

New markets can diversify demand and reduce dependence on a small number of U.S. initiatives.

04
Clinical and operational credibilityshort-term

A CLIA-compliant high-complexity lab supports regulated clinical testing and customer confidence.

Cardio is an early-stage diagnostic company with limited operating history and no significant revenue base, so...

high

Limited operating history and early-stage revenue base

The company has not yet generated significant revenue from product sales and has incurred losses since inception.

Scope
Company-wide commercialization and funding needs
Materiality
high
high

Intense competition from established diagnostic modalities

Serum lipid, proteomic, and imaging-based tests have larger market share, more resources, and established reimbursement strategies.

Scope
Market share, pricing, and adoption
Materiality
high
high

Regulatory and laboratory compliance

Clinical testing depends on CLIA-compliant operations and adherence to licensing obligations.

Scope
Ability to operate and commercialize tests
Materiality
high
medium

Slow provider onboarding and long sales cycles

Management disclosed partnership and sales cycles as long as 24 months and a one- to three-quarter ramp after onboarding.

Scope
Revenue timing and forecasting
Materiality
high
medium

Cybersecurity and PHI protection

The company relies on third parties for storage and transmission of customer and patient data.

Scope
Data privacy, legal liability, reputation
Materiality
medium
Revenue recognition for test services
Can create quarter-to-quarter volatility and affect comparability
Stock-based compensation
Can materially affect operating loss and non-cash expense trends
Estimates and judgments
Reported results may differ materially from future outcomes
License agreement and intangible rights
Could affect access to the underlying technology and going-concern analysis

iRhythm Holdings, Inc.

IRTC · Surgical & Medical Instruments & Apparatus

BIOTRICITY INC.

BTCY · Surgical & Medical Instruments & Apparatus

Integer Holdings Corp

ITGR · Electromedical & Electrotherapeutic Apparatus

Heartflow, Inc.

HTFL · Surgical & Medical Instruments & Apparatus

HeartBeam, Inc.

BEAT · Surgical & Medical Instruments & Apparatus

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

: 28.4.2026